Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0U7SH
|
|||
Former ID |
DIB006254
|
|||
Drug Name |
Desmopressin
|
|||
Synonyms |
Ddavp; DESMOPRESSIN; DDAVP; dAVP; Minirin; Adiuretin SD; Noctiva; Adiuretin; Deamino Arginine Vasopressin; Desmopressinum; deamino-vasopressin; [deamino1]AVP; Desmopressin [INN:BAN]; [deamino-Cys1]AVP; Desmopressinum [INN-Latin]; Desmopressine [INN-French]; Desmopresina [INN-Spanish]; Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-; desnopressin; Vasopressin, Deamino Arginine; EINECS 240-726-7; 1-Desamino-8-D-arginine vasopressin; Desamino-8-D-arginine vasopressin, l-; Deamino-8-D-arginine, l-, vasopressin; Desmopressin Melt; Minrin Melt; FE-992026; Desmopressin (fast-dissolving, nocturia/diabetes insipidus); Desmopressin (fast-dissolving, nocturia/diabetes insipidus), Ferring Pharmaceuticals
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Diabetic complication [ICD-11: 5A2Y; ICD-9: 253.5, 588.1] | Approved | [1], [2], [3] | |
Company |
Ferring Pharmaceuticals Inc
|
|||
Structure |
Download2D MOL
|
|||
Formula |
C46H64N14O12S2
|
|||
Canonical SMILES |
C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N
|
|||
InChI |
1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1
|
|||
InChIKey |
NFLWUMRGJYTJIN-PNIOQBSNSA-N
|
|||
CAS Number |
CAS 16679-58-6
|
|||
PubChem Compound ID | ||||
PubChem Substance ID | ||||
ChEBI ID |
CHEBI:4450
|
|||
ADReCS Drug ID | BADD_D00616 ; BADD_D00617 |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2182). | |||
REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
REF 3 | ClinicalTrials.gov (NCT00748072) 1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy. U.S. National Institutes of Health. | |||
REF 4 | Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. | |||
REF 5 | Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90. | |||
REF 6 | Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest. 2000 Jul;106(1):107-16. | |||
REF 7 | The abnormal quinine drinking aversion in the Brattleboro rat with diabetes insipidus is reversed by the vasopressin agonist DDAVP: a possible role for vasopressin in the motivation to drink. PhysiolBehav. 1994 Mar;55(3):407-12. | |||
REF 8 | Hydronephrosis: prevention by restoration of urinary concentrating ability using desamino-8D-arginine vasopressin (DDAVP) in Brattleboro rats. Int J Exp Pathol. 1991 Oct;72(5):581-7. | |||
REF 9 | An extracellular residue determines the agonist specificity of V2 vasopressin receptors. FEBS Lett. 1995 Mar 27;362(1):19-23. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.